期刊文献+

探讨微汗法是祛除新型冠状病毒和炎症风暴的基本原则 被引量:10

Slight diaphoresis is an essential principle to erase novel coronavirus andcalm cytokine storm
下载PDF
导出
摘要 细胞中生化反应的总体趋势是能量物质氧化形成代谢终产物。细胞中连接能量物质和代谢终产物的所有代谢过程大都是少阳经的生理基础。细胞内归属少阳经的代谢过程又可以划分为四个层次,分别归入少阳经的气分和少阳经的血分。新型冠状病毒的复制和传播以及炎症介质、细胞因子的合成和释放都在少阳经的血分中完成,并具相同的代谢背景:细胞内的水热排泄障碍,丰富的能量物质,氧气摄取障碍。杀灭病毒和灭活细胞因子依靠细胞内的氧化过程,包括细胞内自噬过程。由此,人体肺部病毒繁殖和炎症风暴形成的中医辨证就是太阳伤寒合并阳明和少阳郁热。微汗法是清除病毒和阻止炎症风暴形成的基本治疗原则。同时,太阳经证、表证寒气未除的情况下,不能单纯清解阳明经和少阳经中热邪,寒性食物和药物应成为禁忌。 The trend of all metabolisms in a living cell is to oxidize all energy agents into end metabolites.Those pathways connecting the energy agents and end metabolite is defined as the physiology of Shaoyang meridian.All metabolisms in Shaoyang meridian can be divided into four metabolic levels and also classified into Qifeng and xuefen in Shaoyang meridian respectively.Both the proliferation of novel coronavirus(COVID-19)and the synthesis of all cytokines are conducted in the xuefen of Shaoyang meridian with the same the metabolic background:attenuated dissipation of heat and water,sufficient energy agents and oxygen in short.It is the oxidation in a living cell to clear the virus and calm cytokine storm and the autophagy is the initial step in this process.So,in traditional Chinese medicine(TCM),proliferation of COVID-19 and cytokine storm can be diagnosed as cold in Taiyang meridian with heat retention in both Yangming and Shaoyang meridian.Slight diaphoresis is an essential principle to erase the virus and calm cytokine storm.A contraindication is to therapy the heat retention in Yangming or Shaoyang meridian when cold is still staying in Tiayng meridian.
作者 方辉 杨介钻 肖党生 不详 Fang Hui;Yang Jiezuan;Xiao Dangsheng
出处 《中医临床研究》 2020年第6期82-85,共4页 Clinical Journal Of Chinese Medicine
关键词 新冠肺炎 炎症风暴 微汗法 少阳经 太阳经 COVID-19 Cytokine storm Diaphoresis Shaoyang meridian Taiyang meridian
  • 相关文献

参考文献11

二级参考文献39

  • 1张永忠.论中医学人体之气的实质是新陈代谢[J].中国中医基础医学杂志,2000,6(5):8-12. 被引量:35
  • 2张进,徐志伟,陈群,丁富平.干细胞与中医基础理论中的先天之精学说(英文)[J].中国临床康复,2006,10(7):189-192. 被引量:72
  • 3周爱儒.生物化学[M].北京:人民卫生出版社,2003.406-413.
  • 4傅松滨.医学生物学[M].北京:人民卫生出版社,2004.16-56.
  • 5宋金丹,杨恬,李丰,等,医学细胞生物学[M].北京:人民卫生出版社,2004:244-258.
  • 6Toovey S,Rayner C,Prinssen E. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir:a comprehensive review[J].Drug Safety,2008,(12):1097-1114.
  • 7World Health Organization. WHO guidelines for pharmacological management of pandemic(H1N1) 2009 influenza and other influenza viruses[EB/OL].http://www.who.int/csr/resources/publications/swineflu/h1n1_use_antivirals_20090820,2012.
  • 8Centers for Disease Control and Prevention. 2011-2012 Influenza antiviral medications:a summary for clinicians[EB/OL].http://www.cdc.gov/flu/pdf/professi onals/antivirals/clinician-antivirals-2011.pdf,2012.
  • 9Quality Assurance and Safety of Medicines. WHO Drug Information[EB/OL].http://www.who.int/medicines/publications/druginformation/issues/DrugInfo05vol19_4/en/index.html,2012.
  • 10U.S.Food and Drug Administration. Tamiflu pediatric adverse events:questions and answers[EB/OL].http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107840.htm,2012.

共引文献2814

同被引文献109

引证文献10

二级引证文献88

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部